ArticleBMC immunology2025
Pattern of sensitization to yellow jacket venom and expression of recombinant antigen 5 (Ves v 5) from yellow jacket venom.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHymenoptera venom allergy is a significant allergic reaction that affects a substantial proportion of adults. Accurate diagnosis of this allergy using venom extracts is challenging due to molecular cross-reactivity. Pure recombinant allergens offer a promising solution to identify the specific venom responsible for allergic reactions. This study aimed to produce recombinant phospholipase A5 (Ves v 5) from yellow jacket venom and evaluate the pattern of bee venom sensitization in a group of sensitive patients. METHODS AND
resultsA total of seven individuals, including four sensitive and three non-sensitive participants, were recruited for this study. Blood samples were collected, and serum was isolated to assess susceptibility to bee venom and recombinant allergens. Expression of Ves v 5 in Escherichia coli resulted in the production of soluble proteins, which were subsequently purified through affinity chromatography. The functionality of the recombinant allergens was evaluated through enzymatic and biophysical analyses, such as dot blot and SDS‒PAGE tests. The diagnostic relevance of Ves v 5 was further investigated using ELISA-based analyses of sera from yellow jacket venom-sensitized patients. Successful production of soluble Ves v 5 in Escherichia coli was achieved. The recombinant Ves v 5 exhibited distinct biochemical and functional characteristics. Evaluation of IgE reactivity in sera from patients underscored the importance of Ves v 5 in hymenoptera venom allergy.
conclusionsOur findings suggest that recombinant allergens can serve as an alternative to natural extracts for diagnostic purposes. Furthermore, allergen-specific immunotherapy holds the potential to enhance efficiency and specificity in the treatment of hymenoptera venom allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.